Background: Since its first description in 1984, periacetabular osteotomy (PAO) has become an accepted treatment for hip dysplasia. The 30-year survivorship with this procedure has not been reported. Because these patients are often very young at the time of surgery, long-term followup and identification of factors associated with poor outcome could help to improve patient selection.

Questions/purposes: Looking at the initial group of patients with hip dysplasia undergoing PAO at the originator's institution, we asked: (1) What is the cumulative 30-year survival rate free from conversion to THA, radiographic progression of osteoarthritis, and/or a Merle d'Aubigné-Postel score < 15? (2) Did hip function improve and pain decrease? (3) Did radiographic osteoarthritis progress? (4) What are the factors associated with one or more of the three endpoints: THA, radiographic progression of osteoarthritis, and/or Merle d'Aubigné-Postel score < 15?

Methods: We retrospectively evaluated the first 63 patients (75 hips) who underwent PAO for hip dysplasia between 1984 and 1987. At that time, hip dysplasia was the only indication for PAO and no patients with acetabular retroversion, the second indication for a PAO performed today, were included. During that period, no other surgical treatment for hip dysplasia in patients with closed triradiate cartilage was performed. Advanced osteoarthritis (≥ Grade 2 according to Tönnis) was present preoperatively in 18 hips (24%) and 22 patients (23 hips [31%]) had previous femoral and/or acetabular surgery. Thirty-nine patients (42 hips [56%]) were converted to a THA and one patient (one hip [1%]) had hip fusion at latest followup. Two patients (three hips [4%]) died from a cause unrelated to surgery 6 and 16 years after surgery with an uneventful followup. From the remaining 21 patients (29 hips), the mean followup was 29 years (range, 27-32 years). Of those, five patients (six hips [8%]) did not return for the most recent followup and only a questionnaire was available. The cumulative survivorship of the hip according to Kaplan-Meier was calculated if any of the three endpoints, including conversion to THA, progression of osteoarthritis by at least one grade according to Tönnis, and/or a Merle d'Aubigné-Postel score < 15, occurred. Hip pain and function were assessed with Merle d'Aubigné-Postel score, Harris hip score, limp, and anterior and posterior impingement tests. Progression of radiographic osteoarthritis was assessed with Tönnis grades. A Cox regression model was used to calculate factors associated with the previously defined endpoints.

Results: The cumulative survivorship free from conversion to THA, radiographic progression of osteoarthritis, and/or Merle d'Aubigné-Postel score < 15 was 29% (95% confidence interval, 17%-42%) at 30 years. No improvement was found for either the Merle d'Aubigné-Postel (15 ± 2 versus 16 ± 2, p = 0.144) or Harris hip score (83 ± 11 versus 85 ± 17, p = 0.602). The percentage of a positive anterior impingement test (39% versus 14%, p = 0.005) decreased at 30-year followup, whereas the percentage of a positive posterior impingement test (14% versus 3%, p = 0.592) did not decrease. The percentage of positive limp decreased from preoperatively 66% to 18% at 30-year followup (p < 0.001). Mean osteoarthritis grade (Tönnis) increased from preoperatively 0.8 ± 1 (0-3) to 2.1 ± 1 (0-3) at 30-year followup (p < 0.001). Ten factors associated with poor outcome defined as THA, radiographic progression of osteoarthritis, and/or Merle d'Aubigné-Postel score < 15 were found: preoperative age > 40 years (hazard ratio [HR] 4.3 [3.7-4.9]), a preoperative Merle d'Aubigné-Postel score < 15 (HR 4.1 [3.5-4.6]), a preoperative Harris hip score < 70 (HR 5.8 [5.2-6.4]), preoperative limp (HR 1.7 [1.4-1.9]), presence of a preoperative positive anterior impingement test (HR 3.6 [3.1-4.2]), presence of a preoperative positive posterior impingement test (HR 2.5 [1.7-3.2]), a preoperative internal rotation of < 20° (HR 4.3 [3.7-4.9]), a preoperative Tönnis Grade > 1 (HR 5.7 [5.0-6.4]), a postoperative anterior coverage > 27% (HR 3.2 [2.5-3.9]), and a postoperative acetabular retroversion (HR 4.8 [3.4-6.3]).

Conclusions: Thirty years postoperatively, 29% of hips undergoing PAO for hip dysplasia can be preserved, but more than 70% will develop progressive osteoarthritis, pain, and/or undergo THA. Periacetabular osteotomy is an effective technique to treat symptomatic hip dysplasia in selected and young patients with closed triradiate cartilage. Hips with advanced joint degeneration (osteoarthritis Tönnis Grade ≥ 2) should not be treated with PAO. Postoperative anterior acetabular overcoverage or postoperative acetabular retroversion were associated with decreased joint survival.

Level Of Evidence: Level III, therapeutic study.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339143PMC
http://dx.doi.org/10.1007/s11999-016-5169-5DOI Listing

Publication Analysis

Top Keywords

merle d'aubigné-postel
32
hip dysplasia
28
d'aubigné-postel score
28
progression osteoarthritis
20
and/or merle
20
patients hips
20
conversion tha
16
factors associated
16
tha radiographic
16
radiographic progression
16

Similar Publications

Radiotherapy for oligoprogressive disease in non-small cell lung cancer treated with pembrolizumab in first-line setting: a retrospective study.

Transl Lung Cancer Res

December 2024

Department of Medical Oncology, Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, Paris, France.

Background: Oligoprogression (OP) is common in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICIs). This study aims to assess the benefit and the safety profile of ablative radiotherapy (RT) for OP in mNSCLC treated with pembrolizumab in first-line setting.

Methods: We retrospectively analyzed records of all consecutive mNSCLC patients who underwent treatment with pembrolizumab (+/- chemotherapy) in first-line setting and developed an OP treated with ablative RT while continuing pembrolizumab, in a French Hospital from 2019 to 2022.

View Article and Find Full Text PDF

Background: The process of discharging the critical patient to the ward (discharge from critical care to the general ward-DCCW) is often described as an experience involving uncertainty which may affect the patient's quality of life and ability to cope. Coping with uncertainty is an individual response not related to the course of the illness that is dependent on external and internal resources and the ability to utilize them. Mishel's theory of uncertainty identifies aspects of care that can shape the experience of uncertainty associated with the illness.

View Article and Find Full Text PDF

Recording Lineage History with Cellular Barcodes in the Mammary Epithelium and in Breast Cancer.

Adv Exp Med Biol

January 2025

Laboratory of Genetics and Developmental Biology, Institut Curie, INSERM U934, CNRS UMR3215, Paris, France.

Lineage tracing methods have extensively advanced our understanding of physiological cell behaviour in vivo and in situ and have vastly contributed to decipher the phylogeny and cellular hierarchies during normal and tumour development. In recent years, increasingly complex systems have been developed to track thousands of cells within a given tissue or even entire organisms. Cellular barcoding comprises all techniques designed to genetically label single cells with unique DNA sequences or with a combination of fluorescent proteins, in order to trace their history and lineage production in space and time.

View Article and Find Full Text PDF

Aging is the main risk factor for developing cognitive impairments and associated neurodegenerative diseases. However environmental factors, including nutritional health, are likely to promote or reduce cognitive impairments and neurodegenerative pathologies. An intricate relationship exists between maternal nutrition; and adult eating behavior, metabolic phenotype and cognitive abilities.

View Article and Find Full Text PDF

Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.

J Hepatol

January 2025

Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917). Electronic address:

Background And Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for treatment of compensated chronic hepatitis due to Delta virus (HDV) infection, however real-life data in large cohorts of patients with cirrhosis are lacking.

Methods: Consecutive HDV-infected patients with cirrhosis starting BLV 2 mg/day since September 2019 were included in a European retrospective multicenter real-life study (SAVE-D). Patient characteristics before and during BLV treatment were collected.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!